207 related articles for article (PubMed ID: 31790150)
1. Copper-dependent ATP7B up-regulation drives the resistance of TMEM16A-overexpressing head-and-neck cancer models to platinum toxicity.
Vyas A; Duvvuri U; Kiselyov K
Biochem J; 2019 Dec; 476(24):3705-3719. PubMed ID: 31790150
[TBL] [Abstract][Full Text] [Related]
2. Lysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy.
Vyas A; Gomez-Casal R; Cruz-Rangel S; Villanueva H; Sikora AG; Rajagopalan P; Basu D; Pacheco J; Hammond GRV; Kiselyov K; Duvvuri U
Proc Natl Acad Sci U S A; 2022 Mar; 119(12):e2100670119. PubMed ID: 35286200
[TBL] [Abstract][Full Text] [Related]
3. TFEB Regulates ATP7B Expression to Promote Platinum Chemoresistance in Human Ovarian Cancer Cells.
Petruzzelli R; Mariniello M; De Cegli R; Catalano F; Guida F; Di Schiavi E; Polishchuk RS
Cells; 2022 Jan; 11(2):. PubMed ID: 35053335
[TBL] [Abstract][Full Text] [Related]
4. p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer.
Yassin-Kassab A; Chatterjee S; Khan N; Wang N; Sandulache VC; Huang EH; Burns TF; Duvvuri U
BMC Cancer; 2024 Feb; 24(1):233. PubMed ID: 38373988
[TBL] [Abstract][Full Text] [Related]
5. Sensitization of cancer cells towards Cisplatin and Carboplatin by protein kinase D inhibitors through modulation of ATP7A/B (copper transport ATPases).
Janardhanan P; Somasundaran AK; Balakrishnan AJ; Pilankatta R
Cancer Treat Res Commun; 2022; 32():100613. PubMed ID: 35908410
[TBL] [Abstract][Full Text] [Related]
6. TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression.
Godse NR; Khan N; Yochum ZA; Gomez-Casal R; Kemp C; Shiwarski DJ; Seethala RS; Kulich S; Seshadri M; Burns TF; Duvvuri U
Clin Cancer Res; 2017 Dec; 23(23):7324-7332. PubMed ID: 28899969
[No Abstract] [Full Text] [Related]
7. Novel mechanism of cisplatin resistance in head and neck squamous cell carcinoma involving extracellular vesicles and a copper transporter system.
Ogawa T; Ono K; Ryumon S; Kawai H; Nakamura T; Umemori K; Yoshida K; Kanemoto H; Obata K; Yoshioka N; Okui T; Okamoto K; Nagatsuka H; Ibaragi S
Head Neck; 2024 Mar; 46(3):636-650. PubMed ID: 38164660
[TBL] [Abstract][Full Text] [Related]
8. Copper ions are novel therapeutic agents for uterine leiomyosarcoma.
Kakuda M; Matsuzaki S; Ueda Y; Shiomi M; Matsuzaki S; Kimura T; Fujita M; Egawa-Takata T; Kobayashi E; Serada S; Yoshino K; Naka T; Kimura T
Am J Obstet Gynecol; 2020 Jan; 222(1):64.e1-64.e16. PubMed ID: 31351063
[TBL] [Abstract][Full Text] [Related]
9. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts.
Nakagawa T; Inoue Y; Kodama H; Yamazaki H; Kawai K; Suemizu H; Masuda R; Iwazaki M; Yamada S; Ueyama Y; Inoue H; Nakamura M
Oncol Rep; 2008 Aug; 20(2):265-70. PubMed ID: 18636185
[TBL] [Abstract][Full Text] [Related]
10. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer.
Lukanović D; Herzog M; Kobal B; Černe K
Biomed Pharmacother; 2020 Sep; 129():110401. PubMed ID: 32570116
[TBL] [Abstract][Full Text] [Related]
11. Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug.
Leonhardt K; Gebhardt R; Mössner J; Lutsenko S; Huster D
J Biol Chem; 2009 Mar; 284(12):7793-802. PubMed ID: 19141620
[TBL] [Abstract][Full Text] [Related]
12. Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines.
Nakayama K; Miyazaki K; Kanzaki A; Fukumoto M; Takebayashi Y
Oncol Rep; 2001; 8(6):1285-7. PubMed ID: 11605050
[TBL] [Abstract][Full Text] [Related]
13. Cell-specific mechanisms of TMEM16A Ca
Wang H; Zou L; Ma K; Yu J; Wu H; Wei M; Xiao Q
Mol Cancer; 2017 Sep; 16(1):152. PubMed ID: 28893247
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B.
Dmitriev OY
Biochem Cell Biol; 2011 Apr; 89(2):138-47. PubMed ID: 21455266
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.
Samimi G; Katano K; Holzer AK; Safaei R; Howell SB
Mol Pharmacol; 2004 Jul; 66(1):25-32. PubMed ID: 15213293
[TBL] [Abstract][Full Text] [Related]
16. Ammonium tetrathiomolybdate enhances the antitumor effect of cisplatin via the suppression of ATPase copper transporting beta in head and neck squamous cell carcinoma.
Ryumon S; Okui T; Kunisada Y; Kishimoto K; Shimo T; Hasegawa K; Ibaragi S; Akiyama K; Thu Ha NT; Monsur Hassan NM; Sasaki A
Oncol Rep; 2019 Dec; 42(6):2611-2621. PubMed ID: 31638244
[TBL] [Abstract][Full Text] [Related]
17. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK
Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734
[TBL] [Abstract][Full Text] [Related]
19. To "grow" or "go": TMEM16A expression as a switch between tumor growth and metastasis in SCCHN.
Shiwarski DJ; Shao C; Bill A; Kim J; Xiao D; Bertrand CA; Seethala RS; Sano D; Myers JN; Ha P; Grandis J; Gaither LA; Puthenveedu MA; Duvvuri U
Clin Cancer Res; 2014 Sep; 20(17):4673-88. PubMed ID: 24919570
[TBL] [Abstract][Full Text] [Related]
20. Role of copper transporters in resistance to platinating agents.
Rabik CA; Maryon EB; Kasza K; Shafer JT; Bartnik CM; Dolan ME
Cancer Chemother Pharmacol; 2009 Jun; 64(1):133-42. PubMed ID: 18998134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
